In the HOPE study, investigators tested the use of PDOs to predict a patient’s response to treatment, says Hidalgo Medina. Results from the study indicated that PDOs could help personalize therapy for patients with pancreatic cancer and ultimately, spare them the toxicities that are associated with ineffective treatments. Read more . . .
Manuel Hidalgo Medina, MD, PhD, chief, Division of Hematology and Medical Oncology, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses that rationale for using patient-derived organoids (PDOs) in pancreatic cancer.